Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

ASCO 2021 and Gastrointestinal Cancer View overview page

1:55
AVANA: preoperative chemo-RT plus avelumab in locally advanced rectal cancer
Lisa Salvatore • 11 Jun 2021
4:24
NIFTY: liposomal irinotecan in combination with 5FU and leucovorin in patients with mBTC
Changhoon Yoo • 15 Jun 2021
1:56
Improving outcomes in HCC with immunotherapy
Arndt Vogel • 11 Jun 2021
4:59
CheckMate 648: 1L IO-IO in advanced esophageal squamous cell carcinoma
Ian Chau • 15 Jun 2021
5:18
Checkmate577: nivolumab in EC/GEJC
Ronan Joseph Kelly • 11 Jun 2021
4:07
80mg regorafenib plus pembrolizumab for 1L HCC
Richard D. Kim • 10 Jun 2021
2:41
Liposomal irinotecan plus 5-FU & leucovorin for patients with metastatic BTC
Richard D. Kim • 10 Jun 2021
2:36
Real-world use of nivolumab in gastric cancer
Yu Sunakawa • 8 Jun 2021
2:45
1L FOLFOXIRI plus cetuximab or bevacizumab for RAS wild-type mCRC
Yu Sunakawa • 8 Jun 2021
7:21
Neo-AEGIS: preliminary results of the Phase III RCT of CROSS versus perioperative chemotherapy
John V. Reynolds • 27 May 2021
2:14
Immunotherapy of NETs
Jonathan Strosberg • 7 Jun 2021
11:32
Final results from DESTINY-CRC01: T-Dxd in HER2-expressing mCRC
Mohamed E. Salem • 9 Jun 2021
4:03
Phase I/II trial of zenocutuzumab for tumors with NRG1 fusions
Alison M. Schram • 4 Jun 2021
6:54
CheckMate 649: 1L nivo + chemotherapy improves OS
Mohamed E. Salem • 9 Jun 2021
1:25
The IMMULAB trial: pembrolizumab with local ablation for patients with early-stage HCC
Arndt Vogel • 11 Jun 2021
2:40
FIGHT-202: pemigatinib for FGFR2 altered CCA
Arndt Vogel • 11 Jun 2021
The content of VJOncology is intended for healthcare professionals